Home Wires

Are we getting an opportunity now to buy ResMed?

Michael Gable

Fairmont Equities

The share price of ResMed (RMD) has shed almost 10 per cent since the start of August. It’s now trading on a P/E of ~20x, compared to ~24x around the time of their fiscal year result. There are however some concerns in the market about an expected impact on gross margins from pricing pressure from its US customers. Looking at the chart, we are can also identify some key levels that RMD needs to respect. (VIEW LINK)

1 stock mentioned

Michael Gable
Michael Gable
Managing Director
Fairmont Equities

Michael Gable is managing director of Fairmont Equities. We are a small boutique advisory that uniquely combines both fundamental and technical analysis. As a result, our analysis is featured regularly in the finance media such as the Australian...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment

most popular

Equities

Why my mum might help pop the CBA bubble

Elston Asset Management

Funds

The top-performing alternative asset funds for FY25

Livewire Markets

Equities

Is the end of globalisation the end of global equity investing? The follow up...

Arteqin Capital Limited

Funds

The top 5 global equity funds delivered more than 37% in a volatile FY25

Livewire Markets

view all